Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
Previous Symbol
CUSIP37416310
Phone650-473-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio37.86
Quick Ratio37.86
Price-To-Earnings
Trailing P/E Ratio-7.78
Forward P/E Ratio-7.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 million
Price / Sales243.82
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.65 per share
Price / Book2.15
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-3,077.78%
Return on Equity-19.16%
Return on Assets-18.50%
Miscellaneous
Employees18
Outstanding Shares186,350,000
Market Cap$277.66 million
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) issued its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The biopharmaceutical company earned $0.17 million during the quarter, compared to analyst estimates of $0.22 million. Geron had a negative return on equity of 19.16% and a negative net margin of 3,077.78%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
4 Wall Street analysts have issued twelve-month price targets for Geron's stock. Their predictions range from $1.50 to $7.00. On average, they expect Geron's share price to reach $3.5750 in the next year. This suggests a possible upside of 155.4% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
Headlines about GERN stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Geron earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Are investors shorting Geron?
Geron saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 31,875,061 shares, an increase of 6.4% from the November 15th total of 29,970,792 shares. Based on an average daily volume of 2,550,492 shares, the short-interest ratio is currently 12.5 days. Currently, 17.2% of the shares of the stock are sold short. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Deciphera Pharmaceuticals (DCPH), Amphastar Pharmaceuticals (AMPH), Apellis Pharmaceuticals (APLS), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX) and Dicerna Pharmaceuticals (DRNA).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
- Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
- Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
- Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)
Who are Geron's major shareholders?
Geron's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.48%), Vanguard Group Inc. (4.70%), FMR LLC (3.23%), State of New Jersey Common Pension Fund D (0.28%), Teachers Advisors LLC (0.18%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which major investors are selling Geron stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State of New Jersey Common Pension Fund D, Virtus ETF Advisers LLC and Credit Suisse AG. Company insiders that have sold Geron company stock in the last year include Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.
Which major investors are buying Geron stock?
GERN stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Russell Investments Group Ltd., Seven Eight Capital LP, M Holdings Securities Inc., Paloma Partners Management Co, MetLife Investment Advisors LLC and Teachers Advisors LLC. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.40.
How big of a company is Geron?
Geron has a market capitalization of $277.66 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
